Skip to main content

Advertisement

SpringerLink
Log in

SEOM clinical guidelines for the treatment of invasive bladder cancer

  • Clinical Guides in Oncology
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

The purpose of this article is to provide updated recommendations for the diagnosis and treatment of muscle-invasive and metastatic bladder cancer. The diagnosis of muscle-invasive bladder cancer is made by transurethral resection and following histopathologic evaluation. Invasive bladder cancer should be staged according to the UICC system. Patients with confirmed muscle-invasive bladder cancer should be staged by computed tomography scans of the chest, abdomen and pelvis. Radical cystectomy is the treatment of choice for both sexes and lymph node dissection should be an integral part of cystectomy. In muscle-invasive bladder cancer (cT2-4aN0M0) patients with good performance status (PS 0–1) and correct renal function, neoadjuvant chemotherapy should be recommended. Adjuvant chemotherapy is widely used in high-risk patients with pathologic stage T3 or T4 and/or positive nodes and within clinical trials. Multimodality bladder-preserving treatment in localised disease is currently regarded only as an alternative in selected, well informed and compliant patients for whom cystectomy is not considered for clinical or personal reasons. In metastatic disease, the first-line treatment for patients is cisplatin-containing combination chemotherapy. Recently, vinflunine has been approved in Europe for second-line treatment and is an option for second-line therapy in patients progressing to first-line platinum-based chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferlay J, Parkin DM, Steliarova-Foucher E et al (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765–781

    Article  PubMed  CAS  Google Scholar 

  2. http://www.msps.es/ciudadanos/enfLesiones/enf-NoTransmisibles/docs/situacionCancer.pdf (Accessed Nov 2010)

  3. Kaufman DS, Shipley WU, Feldman AS et al (2009) Bladder cancer. Lancet 374:239–249

    Article  PubMed  CAS  Google Scholar 

  4. Chalasani V, Chin JL, Izawa JI et al (2009) Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J 3[6 Suppl 4]:S193–198

    PubMed  Google Scholar 

  5. Svatek RS, Siefker-Radtke A, Dinney CP et al (2009) Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy. Can Urol Assoc J 3[6 Suppl 4]:S228–231

    PubMed  Google Scholar 

  6. Edge SB, Byrd DR, Compton CC et al (2010) Urinary bladder. In: AJCC Cancer Staging Manual, 7th edn. Springer, New York, pp 497–502

    Google Scholar 

  7. Mallampati GK, Siegelman ES (2004) MR imaging of the bladder. Magn Reson Imaging Clin N Am 12:545–555

    Article  PubMed  Google Scholar 

  8. Kim JK, Park SY, Ahn HJ et al (2004) Bladder cancer: analysis of multi-detector row helical CT enhancenment pattern and accuracy in tumor detection and perivesical staging. Radiology 231: 725–731

    Article  PubMed  Google Scholar 

  9. Kibel AS, Dehdashti F, Katz MD et al (2009) Prospective study of 18F Fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 27:4314–4320

    Article  PubMed  Google Scholar 

  10. Apolo AB, Riches J, Schoder H et al (2010) Clinical value of fluorine-18 2-fluoro-2-deoxy-Dglucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol 28: 3973–3978

    Article  PubMed  Google Scholar 

  11. Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 19:666–675

    PubMed  CAS  Google Scholar 

  12. Karl A, Carroll PR, Gschwend JE et al (2009) The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol 55:826–835

    Article  PubMed  Google Scholar 

  13. Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866

    Article  PubMed  CAS  Google Scholar 

  14. Herr HW, Faulkner JR, Grossman HB et al (2004) Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 22:2781–2789

    Article  PubMed  Google Scholar 

  15. International Collaboration of Trialists (1999) Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354:533–540

    Article  Google Scholar 

  16. Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361:1927–1934

    Article  Google Scholar 

  17. Winquist E, Kirchner TS, Segal R et al (2004) Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 171:561–569

    Article  PubMed  CAS  Google Scholar 

  18. Vale CA, Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration (2005) Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur Urol 48:189–201

    Article  Google Scholar 

  19. Paz-Ares LG, Solsona E, Esteban E et al (2010) Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. Proc Am Soc Clin Oncol 28[346s]:abstr 4518

  20. von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077

    PubMed  Google Scholar 

  21. Nogué-Aliguer M, Carles J, Arrivi A et al (2003) Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 97:2180–2186

    Article  PubMed  Google Scholar 

  22. de Wit R (2003) Overview of bladder cancer trials in the European Organization for Research and Treatment. Cancer 97:2120–2126

    Article  PubMed  Google Scholar 

  23. Sternberg CN, Yagoda A, Scher HI et al (1985) Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133:403–407

    PubMed  CAS  Google Scholar 

  24. Loehrer PJ Sr, Einhorn LH, Elson PJ et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066–1073

    PubMed  Google Scholar 

  25. Logothetis CJ, Dexeus FH, Finn L et al (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050–1055

    PubMed  CAS  Google Scholar 

  26. Sternberg CN, de Mulder PH, Schornagel JH et al (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19:2638–2646

    PubMed  CAS  Google Scholar 

  27. Agarwal N, Hussain M (2009) Management of bladder cancer: current and emerging strategies. Drugs 69:1173–1187

    Article  PubMed  CAS  Google Scholar 

  28. von der Maase H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602–4608

    Article  PubMed  Google Scholar 

  29. Bellmunt J, von der Maase H, Mead GM et al (2007) Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy. EORTC30987/Intergroup Study. Proc Am Soc Clin Oncol 25[18S]: LBA5030

    Google Scholar 

  30. De Santis M, Bellmunt J, Mead G et al (2010) Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase III results of EORTC study 30986. Proc Am Soc Clin Oncol 28[18S]:LBA4519

    Google Scholar 

  31. Bajorin DF, Dodd PM, Mazumdar M et al (1999) Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173–3181

    PubMed  CAS  Google Scholar 

  32. Sonpavde G, Sternberg CN, Rosenberg JE et al (2010) Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 11:861–870

    Article  PubMed  CAS  Google Scholar 

  33. Bellmunt J, Théodore C, Demkov T et al (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27:4454–4456

    Article  PubMed  CAS  Google Scholar 

  34. Bellmunt J, Choueiri TK, Fougeray R et al (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinumcontaining regimens. J Clin Oncol 28:1850–1855

    Article  PubMed  Google Scholar 

  35. Rödel C, Weiss C, Sauer R et al (2006) Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 24:5536–5544

    Article  PubMed  Google Scholar 

  36. Solsona E, Iborra I, Ricós JV et al (1992) Feasibility of transurethral resection for muscle-in-filtrating carcinoma of the bladder: prospective study. J Urol 147:1513–1515

    PubMed  CAS  Google Scholar 

  37. Herr HW (1987) Conservative management of muscle infiltrating bladder cancer: prospective experience. J Urol 138:1162–1163

    PubMed  CAS  Google Scholar 

  38. Solsona E, Iborra I, Collado A et al (2010) Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol 184:475–480

    Article  PubMed  Google Scholar 

  39. Munro NP, Sundaram SK, Weston PM et al (2010) A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK. Int J Radiat Oncol Biol Phys 77:119–124

    Article  PubMed  Google Scholar 

  40. Jahnson S, Damm O, Hellsten S et al (2009) A population-based study of patterns of care for muscle-invasive bladder cancer in Sweden. Scand J Urol Nephrol 43:271–276

    Article  PubMed  Google Scholar 

  41. Rödel C, Grabenbauer GG, Kühn R et al (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20:3061–3071

    Article  PubMed  Google Scholar 

  42. Shipley WU, Winter KA, Kaufman DS et al (1998) Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16:3576–3583

    PubMed  CAS  Google Scholar 

  43. Hagan MP, Winter KA, Kaufman DS et al (2003) RTOG 97-06: Initial report of a phase I–II trial of selective bladder conservation using TURBT, twice daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 57:665–672

    Article  PubMed  Google Scholar 

  44. Coppin CM, Gospodarowicz MK, James K et al (1996) Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol 14:2901–2907

    PubMed  CAS  Google Scholar 

  45. James ND, Hussain E, Hall P et al (2010) Results of a phase III randomized trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle invasive bladder cancer (MIBC) (BC2001 CRUK/01/004). J Clin Oncol 28[15s]:abstr 4517

  46. Hoskin P, Rojas A, Bentzen S et al (2010) Radiotherapy with concurrent carbogen and nicotinamide in bladder cancer. J Clin Oncol (Epub ahead of print)

  47. Cagiannos I, Morash C (2009) Surveillance strategies after definitive therapy of invasive bladder cancer. Can Urol Assoc J 3[Suppl 4]:S237–242

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology Department, Vall d’Hebron University Hospital, Passeig Vall d’Hebron, 119-129, ES-08035, Barcelona, Spain

    Rafael Morales & Joan Carles

  2. Oncology Service, Germans Trias i Pujol University Hospital Badalona, Barcelona, Spain

    Albert Font

  3. Medical Oncology Department, Hospital Lozano Blesa, Zaragoza, Spain

    Dolores Isla

Authors
  1. Rafael Morales
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Albert Font
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joan Carles
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dolores Isla
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joan Carles.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morales, R., Font, A., Carles, J. et al. SEOM clinical guidelines for the treatment of invasive bladder cancer. Clin Transl Oncol 13, 552–559 (2011). https://doi.org/10.1007/s12094-011-0696-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-011-0696-8

Keywords

Search

Navigation